{"id":"NCT02273050","sponsor":"AstraZeneca","briefTitle":"Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control","officialTitle":"A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-12","primaryCompletion":"2016-08","completion":"2016-08","firstPosted":"2014-10-23","resultsPosted":"2018-02-05","lastUpdate":"2018-02-05"},"enrollment":1136,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Saxagliptin 5 mg","otherNames":["Onglyza","BMS-477118"]},{"type":"DRUG","name":"Placebo 5 mg for Saxagliptin","otherNames":[]},{"type":"DRUG","name":"Placebo 500 mg for metformin (with titration)","otherNames":[]},{"type":"DRUG","name":"Metformin 500 mg with titration","otherNames":["Glucophage"]}],"arms":[{"label":"Saxagliptin 5 mg + Metformin (500 mg with titration)","type":"EXPERIMENTAL"},{"label":"Saxagliptin 5 mg + Placebo","type":"ACTIVE_COMPARATOR"},{"label":"Metformin (500 mg with titration) + Placebo","type":"ACTIVE_COMPARATOR"}],"summary":"A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination with Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects with Type 2 Diabetes who have Inadequate Glycaemic Control","primaryOutcome":{"measure":"Change From Baseline in HbA1c From Baseline to Week 24 Provided That it is Prior to Rescue","timeFrame":"Baseline to Week 24 (prior to rescue)","effectByArm":[{"arm":"Saxagliptin + Metformin","deltaMin":-3.007,"sd":0.0706},{"arm":"Saxagliptin + Placebo","deltaMin":-2.123,"sd":0.0701},{"arm":"Metformin + Placebo","deltaMin":-2.794,"sd":0.0715}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"0.034"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":17,"countries":["China"]},"refs":{"pmids":["28926170"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":210},"commonTop":["Upper respiratory tract infection","Diarrhoea","Hyperlipidaemia"]}}